The Healing Power of Botanical Therapeutics®

 
10-16-2012

Herborium's sexual health product poised to enter $1 billion U.S. market with feauture in USA Today's Sexual Health magazine

Press Release: Herborium Group, Inc. – Tue, Oct 16, 2012 9:00 AM EDT

FORT LEE, N.J., Oct. 16, 2012 /PRNewswire/ -- Herborium Group, Inc., (HBRM) www.herborium.com, a Botanical Therapeutics® Company announced today that its Sexual Products Lasting Pleasure® and Lasting Power® that represent over $1 billion market potential will be featured in upcoming USA Today Sexual Health Magazine on 28, 29 and 30 of October 2012 with over 3 Million readers expected to preview the publication from New York to Los Angeles. In addition, Dr. Agnes P. Olszewski , CEO and Chairwomen of Herborium Group will provide an Editorial for the publication. The publication will also be provided to distributors, retailers and experts at the first Sex Summit Conference in San Francisco on October 27th.

Herborium proprietary all natural sexual health products will debut on the market in November 2012. A new digital media campaign is to be launched on October 28th and will be associated with the Kamasutra™ Spirit marketing strategy. Each bottle of Kamasutra™ and related digital and traditional marketing and sales materials include reference and leads to Herborium products. Herborium Sexual Health Therapeutics are also a subject of market and industry promotion by SSPR (top 20 Public Relations firm in the USA). Products are expected to start generating revenues in the 4th Quarter of 2012 and will also gain the distribution support form Kamasutra sales force.

Herborium received a number of inquiries for distribution arrangements of the products and for private label arrangements, and expects both products to add substantially to the Company's bottom line in 2013.

About Herborium Group, Inc.

Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company uses clinical validation to establish and maintain a differential advantage. The company sells its products in the US and Europe. For more information, please visit www.herborium.com and www.acnease.com

One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.
Investorsrelations@herborium.com: Investorsrelations@herborium.com

 

Information provided on Herborium.com about medical conditions, symptoms, and related products is not intended to be a substitute for professional medical advice. Visitors to this site should not use this information to diagnose or treat a health problem, symptom, concern or disease without consulting with their individual qualified healthcare provider. Statements contained on this website have not been evaluated by the FDA. Herborium products are not intended to diagnose, heal, cure or prevent disease.